Author

K. Blankenship

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:statistical model· 2 Assay:scRNA-seq· 1

Frequent Co-Authors

E. Stewart· 3 shared B. Gordon· 2 shared J. Yu· 2 shared M. A. Dyer· 2 shared S. M. Pruett-Miller· 2 shared A. Bahrami· 1 shared A. G. Patel· 1 shared A. Karlstrom· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

E. Stewart

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The Myogenesis Program Drives Clonal Selection and Drug Resistance in Rhabdomyosarcoma

A. G. Patel, X. Chen, X. Huang, M. R. Clay, N. Komarova, M. J. Krasin, A. Pappo, H. Tillman, B. A. Orr, J. McEvoy, B. Gordon, K. Blankenship, C. Reilly, X. Zhou, J. L. Norrie, , M. A. Dyer

This study shows that targeting developmental states in rhabdomyosarcoma can prevent disease recurrence by eliminating myoblast-like cells and inhibiting EGFR-dependent paraxial mesoderm populations.

bioRxiv · Jun 16, 2021Cancer Biology

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma.

M. Pan, C. Wright, R. Chapple, A. Zubair, M. Sandhu, J. Batchelder, J. Low, K. Blankenship, L. Wang, B. Gordon, P. Archer, S. W. Brady, S. Natarajan, M. Pozsgai, J. Schuetz, , P. Geeleher

This study identifies CX-5461 as a TOP2B inhibitor with selective activity in high-risk neuroblastoma but highlights safety concerns due to TOP2B off-target effects.

bioRxiv · Feb 25, 2021Cancer Biology

Interrogation of SLFN11 in pediatric sarcomas uncovers an unexpected biological role and a novel therapeutic approach to overcoming resistance to replicative stress

J. Gartrell, M. Mellado-Lagarde, N. Martinez, M. Clay, A. Bahrami, N. Sahr, A. Sykes, K. Blankenship, L. Hoffmann, J. Xie, H. P. Cho, N. Twarog, M. Connelly, K.-K. Yan, J. Yu, , A. Shelat

This study investigates SLFN11's role in pediatric sarcomas, finding it promotes tumor growth and resistance to DNA-damaging agents, which can be overcome by BCL-XL inhibition.

bioRxiv · Nov 5, 2020 · PreprintCancer Biology